Background: There is some evidence that statins may have a protective and symptomatic
benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) …

OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy
with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by …

Objectives : We sought to examine the incidence and clinical predictors of new-onset type 2
diabetes mellitus (T2DM) within 3 large randomized trials with atorvastatin. Background : …

Objectives : This subanalysis of the TNT (Treating to New Targets) study investigates the
effects of intensive lipid lowering with atorvastatin in patients with coronary heart disease (CHD) …

Background and objectives: Data suggest that atorvastatin may be nephroprotective. This
subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with …

Objectives : The purpose of this study was to compare the incidence of new-onset diabetes (NOD)
with cardiovascular (CV) event reduction at different levels of NOD risk. Background : …

The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the
cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in …

Background— Cardiovascular events occur among statin-treated patients, albeit at lower
rates. Risk factors for this “residual risk” have not been studied comprehensively. We aimed to …

Background— High-density lipoproteins have antidiabetic properties in vitro. Furthermore,
elevated high-density lipoprotein levels accompanying a genetic deficiency of cholesteryl …

Background : Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C)
using a statin is associated with significant reduction in cardiovascular events. Whether visit-…